Innovation
ASH 24 Posters
GTC presented abstracts at ASH 2024 GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out
December 10, 2024 11:39 am
Read More »
Publications
Liquid biopsy for evaluating mutations & chromosomal aberrations in CSF from patients with primary or metastatic CNS tumors
Just published in The Journal of Liquid Biopsy Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic
December 10, 2024 10:04 am
Innovation
Genomic Testing Cooperative Unveils “GTC Interpret”, a Groundbreaking Web-Based Platform for Partner Labs to Access Analyzed Sequencing Data and Finalize Reports
Lake Forest, CA – November 13, 2024 – Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a
November 13, 2024 4:00 am
Publications
Expanding the Clinical Utility of Liquid Biopsy by Using Liquid Transcriptome and Artificial Intelligence
Maher Albitar, Ahmad Charifa, Sally Agersborg, Andrew Pecora, Andrew Ip, Andre Goy Abstract: Most of the current utilization of liquid biopsy (LBx) is based on
October 22, 2024 11:35 am
Article
BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
June 25, 2024 5:05 am
Publications
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
New publication in New England Journal of Medicine for Genomic Testing Cooperative (GTC). GTC work was in collaboration with Dana-Faber cancer Institute/Harvard Medical School, Georgetown
June 12, 2024 2:05 pm
Publications
Bringing Value to Health Care
New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it
June 11, 2024 11:37 am
Innovation
ASCO 24 Posters
GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
June 5, 2024 9:17 am
Press Releases
CorePath Laboratories Internalizes Genomic Testing Cooperative’s State-Of-The-Art Next-Generation Sequencing (NGS) Testing for Solid Tumors and Hematologic Neoplasms
CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.
May 14, 2024 8:00 am
Publications
Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation
Acute graft-versus-host disease (aGvHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), occurring to some degree in over 50% of patients and being a direct cause of death in about 20% of patients. This complication occurs even despite a better understanding of donor selection and GvHD prophylaxis regimens. aGvHD is a complex event in which multiple contributing factors are involved. We performed RNA transcriptome analysis of 1408 genes in bone marrow samples obtained before and after transplantation using machine learning to predict the risk of aGvHD and post-transplant survival for a cohort of patients undergoing HSCT. Differential gene expression identified several signaling pathways in the bone marrow microenvironment that may be major regulators of the complex biology of GvHD, and identified targets of intervention to ameliorate the risk of aGvHD and improve patient survival.
April 2, 2024 9:20 am